Date: 2017-04-03
Type of information: Nomination
Compound: chief medical officer
Company: Sarepta Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 3, 2017, Sarepta Therapeutics, announced the appointment of Catherine Stehman-Breen as chief medical officer. Dr. Stehman-Breen joins Sarepta after having served as vice president, clinical development and regulatory affairs at Regeneron Pharmaceuticals since 2015, initially as head, pain therapeutic area, and subsequently as head, clinical project management and operations.
- From 2003 to 2015, she held senior leadership roles at Amgen including vice president, global development, leading the neuroscience, nephrology and bone therapeutic areas.
Financial terms:
Latest news:
Is general: Yes
